文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

肾素-血管紧张素-醛固酮系统抑制剂使用与需住院COVID-19风险:病例-人群研究

Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study.
PubMed 文献 · Lancet · 2020-05-14
一句话结论RAAS抑制剂不增加需住院COVID-19风险(调整OR 0.94,95%CI 0.77-1.15),不应为预防重症COVID-19而停用。

这项在西班牙马德里开展的病例-人群研究,连续纳入2020年3月1日至24日七家医院1139例PCR确诊需住院的COVID-19成人患者,并从BIFAP数据库按年龄、性别、地区和入院日期1:10随机匹配11390例人群对照。与使用其他降压药相比,使用RAAS抑制剂者需住院COVID-19的调整OR为0.94(95%CI 0.77-1.15);ACEI调整OR 0.80(0.64-1.00),ARB调整OR 1.10(0.88-1.37)。糖尿病患者中使用RAAS抑制剂者风险降低(调整OR 0.53,95%CI 0.34-0.80)。作者结论认为RAAS抑制剂不增加需住院COVID-19风险,不应为预防重症而停用。

要点

  • 与使用其他降压药相比,使用RAAS抑制剂者需住院COVID-19的调整OR为0.94(95%CI 0.77-1.15),未增加风险。
  • ACEI调整OR 0.80(95%CI 0.64-1.00),ARB调整OR 1.10(95%CI 0.88-1.37),均未达统计学显著升高。
  • 糖尿病患者中使用RAAS抑制剂者需住院COVID-19风险降低(调整OR 0.53,95%CI 0.34-0.80)。
  • 不同COVID-19严重程度亚组间调整OR相似。
  • 作者结论:不应为预防重症COVID-19而停用RAAS抑制剂。

适用人群与场景

  • 西班牙马德里七家医院连续纳入的18岁及以上、PCR确诊需住院的COVID-19患者(2020年3月1日至24日入院)。
  • 对照为从BIFAP西班牙初级保健数据库2018年最后可用年份中随机抽取的人群,按年龄、性别、地区(马德里)和入院日期(月、日)1:10个体匹配。

研究设计与关键结果

  • 病例-人群研究,纳入1139例需住院COVID-19病例和11390例人群对照;病例中女性444例(39.0%),平均年龄69.1岁(SD 15.4)。
  • 与使用其他降压药相比,使用RAAS抑制剂者需住院COVID-19的调整OR为0.94(95%CI 0.77-1.15)。
  • ACEI调整OR 0.80(95%CI 0.64-1.00),ARB调整OR 1.10(95%CI 0.88-1.37)。
  • 糖尿病患者中使用RAAS抑制剂者需住院COVID-19风险降低,调整OR 0.53(95%CI 0.34-0.80)。
  • 性别、年龄和背景心血管风险未改变RAAS抑制剂与需住院COVID-19之间的调整OR;不同COVID-19严重程度间调整OR相似。

证据类型、等级与局限

  • 病例-人群研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为RAAS抑制剂不增加需住院COVID-19风险(包括致死病例和入住ICU者),不应为预防重症COVID-19而停用。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Concerns have been raised about the possibility that inhibitors of the renin-angiotensin-aldosterone system (RAAS) could predispose individuals to severe COVID-19; however, epidemiological evidence is lacking. We report the results of a case-population study done in Madrid, Spain, since the outbreak of COVID-19.

METHODS: In this case-population study, we consecutively selected patients aged 18 years or older with a PCR-confirmed diagnosis of COVID-19 requiring admission to hospital from seven hospitals in Madrid, who had been admitted between March 1 and March 24, 2020. As a reference group, we randomly sampled ten patients per case, individually matched for age, sex, region (ie, Madrid), and date of admission to hospital (month and day; index date), from Base de datos para la Investigación Farmacoepidemiológica en Atención Primaria (BIFAP), a Spanish primary health-care database, in its last available year (2018). We extracted information on comorbidities and prescriptions up to the month before index date (ie, current use) from electronic clinical records of both cases and controls. The outcome of interest was admission to hospital of patients with COVID-19. To minimise confounding by indication, the main analysis focused on assessing the association between COVID-19 requiring admission to hospital and use of RAAS inhibitors compared with use of other antihypertensive drugs. We calculated odds ratios (ORs) and 95% CIs, adjusted for age, sex, and cardiovascular comorbidities and risk factors, using conditional logistic regression. The protocol of the study was registered in the EU electronic Register of Post-Authorisation Studies, EUPAS34437.

FINDINGS: We collected data for 1139 cases and 11 390 population controls. Among cases, 444 (39·0%) were female and the mean age was 69·1 years (SD 15·4), and despite being matched on sex and age, a significantly higher proportion of cases had pre-existing cardiovascular disease (OR 1·98, 95% CI 1·62-2·41) and risk factors (1·46, 1·23-1·73) than did controls. Compared with users of other antihypertensive drugs, users of RAAS inhibitors had an adjusted OR for COVID-19 requiring admission to hospital of 0·94 (95% CI 0·77-1·15). No increased risk was observed with either angiotensin-converting enzyme inhibitors (adjusted OR 0·80, 0·64-1·00) or angiotensin-receptor blockers (1·10, 0·88-1·37). Sex, age, and background cardiovascular risk did not modify the adjusted OR between use of RAAS inhibitors and COVID-19 requiring admission to hospital, whereas a decreased risk of COVID-19 requiring admission to hospital was found among patients with diabetes who were users of RAAS inhibitors (adjusted OR 0·53, 95% CI 0·34-0·80). The adjusted ORs were similar across severity degrees of COVID-19.

INTERPRETATION: RAAS inhibitors do not increase the risk of COVID-19 requiring admission to hospital, including fatal cases and those admitted to intensive care units, and should not be discontinued to prevent a severe case of COVID-19.

FUNDING: Instituto de Salud Carlos III.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. de Abajo FJ, Rodríguez-Martín S, Lerma V, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020. PMID: 32416785. doi:10.1016/S0140-6736(20)31030-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。